Jiangsu Recbio Technology Co Ltd (2179) Fair Value & Analysis
Healthcare · HK · Market cap HK$2.9B
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 3 days ago
Share price +2.6% over the past month.
Below-average quality, and screening another 86% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$1.06). The favourable scenario is already priced in.
- Weak quality (19/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (HK$0.5355 to HK$1.06) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
52‑month range HK$3.50 – HK$28.15 · fair‑value band HK$0.5355 – HK$1.06 · the HK$5.13 price screens above the HK$0.7140 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Jiangsu Recbio Technology Co Ltd (2179) currently trades at HK$5.13, while our model-based Fair Value estimate is HK$0.7140, implying the stock looks roughly 86.1% overvalued today. The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at HK$12.7M. Revenue grew 12.0% year over year. It earns a return on equity of -98.8%. Net debt stands at HK$287M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.5355 (bear case) to HK$1.06 (bull case); at HK$5.13, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 51% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at -86%, 2179 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 2179 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 22 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China.
Full company description
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical trial; REC602, recombinant HPV bivalent vaccines targeting HPV type 6/11, which is in phase I clinical trials; REC604a, a novel adjuvanted recombinant HPV quadrivalent vaccine; and REC604c, a recombinant HPV 9-valent vaccine. It also develops REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC625, a bivalent recombinant respiratory syncytial virus vaccine and REC627, a recombinant metapneumovirus vaccine for the treatment of respiratory diseases caused by respiratory syncytial virus; REC609, a recombinant human cytomegalovirus vaccine for the treatment of human cytomegalovirus disease; and ReCOV, a recombinant bicomponent COVID-19 vaccine candidate that completed phase III clinical trial. In addition, the company develops REC629, a recombinant Hepatitis B virus vaccine and REC630, a therapeutic recombinant Hepatitis B virus vaccine for the treatment of disease caused by hepatitis B virus infection; REC608, a recombinant herpes simplex virus vaccine; and REC617, a recombinant influenza vaccine. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jiangsu Recbio Technology Co Ltd reported revenue of HK$12.4M in FY2025 versus HK$6.2M in FY2021, a compound +18.9%/yr. Reported net income was −HK$595M in FY2025.
2179 screens 86% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 605 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.70 | HK$30.58 | -33% |
| Innovent Biologics, Inc 1801 | HK$95.55 | HK$19.68 | -79% |
| Genmab A/S GMAB | kr 2,037 | kr 250.07 | -88% |
| Sino Biopharmaceutical Limited 1177 | HK$4.87 | HK$3.37 | -31% |
| RemeGen Co 688331 | ¥131.87 | ¥23.19 | -82% |
| ALTEOGEN Inc 196170 | 314,000 KRW | 39,476 KRW | -87% |
Compare Jiangsu Recbio Technology Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jiangsu Recbio Technology Co Ltd (2179) overvalued or undervalued?
What is the fair value of 2179?
What is the quality score of 2179?
What is the revenue of Jiangsu Recbio Technology Co Ltd (2179)?
What is the net profit margin of 2179?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jiangsu Recbio Technology Co Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.